小剂量氯胺酮芬太尼复合丙泊酚用于无痛人流

目的探讨小剂量氯胺酮、芬太尼复合丙泊酚用于无痛人流的效果及不良反应,丙泊酚作为基础用药的总量变化,并分别与较大剂量氯胺酮复合丙泊酚、较大剂量芬太尼复合丙泊酚进行对照。方法选择ASAⅠ～Ⅱ级,行人工流产的早孕惠者120例,随机分为3组,K组为氯胺酮0．2mg／kg＋丙泊酚1．5～2mg／kg,F组为芬太尼0．2μg／kg＋丙泊酚1.5～2mg／kg,KF组为氯胺酮0．1mg／kg＋芬太尼0.1μg／kg＋丙泊酚1．5～2mg／kg,各组遇肢体躁动追加丙泊酚,记录术前、术中MAP、HR、SpO2值及丙泊酚用量,不良反应情况。结果KF与K组、F组对照,MAP、SpO2抑制减轻,丙泊酚用量减少,不良反应减少。结论小剂量氯胺酮芬太尼联合丙泊酚用于无痛人流能达到良好的镇痛效果,能减少3种药物用量,减少药物的不良反应。     

氯胺酮或芬太尼复合异丙酚行无痛人流术的效果比较

目的：比较氯胺酮或芬太尼复合异丙酚行无痛人流的效果及安全性。方法：随机选择200例行无痛人流术的早孕妇女，分A、B两组，A组静脉注射氯胺酮0．5mg／kg，异丙酚1．5mg／kg，B组静脉注射芬太尼0．1mg，异丙酚2mg／kg，记录术前、术中、术后的MAP、HR、SpO2变化，异丙酚的用量，术中、术后的镇痛效果。结果：小剂量的氯胺酮复合异丙酚行无痛人流术可提供稳定的血流动力学状态，并减少异丙酚的用量。结论：小剂量的氯胺酮复合异丙酚行无痛人流术较芬太尼复合异丙酚更具安全性，尤其对窦性心动过缓，心律不齐的患者。     

异丙酚复合芬太尼、利多卡因用于无痛人工流产的临床观察

目的 观察异丙酚复合芬太尼、利多卡因静脉麻醉在无痛人工流产术中对患者HR、MAP、SpO2及清醒时间、注射部位疼痛情况的影响。方法 40例择期行无痛人流术的早期妊娠病人随机分成A、B两组。A组开放静脉后先注入利多卡因0．5mg／kg、芬太尼0．5ug／kg，1分钟后注入异丙酚2．5mg／kg，术中根据情况追加30～50mg异丙酚；B组开放静脉后直接注入异丙酚，用量同A组。分别监测两组在麻醉前1分钟、手术开始前、手术中HR、MAP、SpO2变化，并记录病人意识消失时间，清醒时间及注射部位疼痛发生率。结果 A组于手术中HR、MAP升高幅度明显低于B组（P〈0．05）；A组病人注射痛发生率明显低于B组（P〈0．05）；A组SpO2、意识消失及术毕清醒时间与B组相比无显著性差异（P〉0．05）。结论 芬太尼、利多卡因复合异丙酚静脉麻醉用于无痛人工流产术安全、有效，并且能减轻异丙酚引起的注射痛。     

异丙酚及异丙酚复合氯胺酮用于人工流产术的应用观察

目的:比较异丙酚及异丙酚复合氯胺酮用于人工流产术的麻醉效果及不良反应。方法:选择ASAⅠ～Ⅱ级行人工流产的早孕200例,随机分为Ⅰ组与Ⅱ组,Ⅰ组采用异丙酚1～1.5 mg/kg,Ⅱ组采用氯胺酮0.1 mg/kg+异丙酚1～1.5 mg/kg。记录术前和术中平均动脉压(MAP)、心率(HR)、血氧饱和度(SpO2)、异丙酚总用量、不良反应及患者清醒时间、行走恢复时间。结果:Ⅱ组与Ⅰ组比较,MAP、SpO2抑制减轻,异丙酚用量减少,患者清醒时间、行走恢复时间缩短,不良反应少。结论:小剂量氯胺酮联合异丙酚用于人工流产能达到良好的镇痛效果,减少药物用量及药物不良反应。     

异丙酚复合芬太尼或氯胺酮用于人工流产手术麻醉

目的目前无痛人流在普遍开展，但一般用药都比较单一，副作用表现明显，为了使手术更加安全，用药更加合理，我们用异丙酚分别和芬太尼或氯胺酮配伍，以期找到更合理的麻醉方法。方法 60例ASA Ⅰ-Ⅱ级自愿接受无痛人流患者，随机分为三组，A组为对照组20例，给予异丙酚1．5mg／kg；；B组20例，给予异丙酚1．5mg／kg 芬太尼1μg／kg；C组20例，给予异丙酚1．5mg/kg 氯胺酮0．5mg／kg。记录患者意识消失时间(注药开始至意识消失)、意识恢复时间(末次注药至意识恢复)、总用药量、HR、MAP、SpO2、手术时间及不良反应。结果三组比较A组用药量、术中体动反应例数、术后下腹疼痛例数明显多于B、C两组，尤以C组为甚。其中C组用药量最少，诱导时间最短，HR、MAP、SpO2几乎没有变化。结论异丙酚复合亚麻醉剂量的氯胺酮用于人工流产手术，不仅能够达到完全无痛，而且苏醒时间短，用药量少，术中呼吸抑制轻微，生命体征平稳。     

异丙酚复合小剂量氯胺酮用于无痛人流术的临床观察

目的观察异丙酚复合小剂量氯胺酮用于无痛人流术的效果.方法选择30例早孕妇女随机分为F组和FK组,每组15例,K组静注异丙酚2.5mg/kg,FK组先静注氯胺酮0.2mg/kg,然后静注异丙酚1.5mg/kg,异丙酚均于20～40秒内注完,注完后30秒即开始手术.若患者不能耐受手术刺激,则追加维持药量20～40mg.记录注药前1′注药后2′、4′、6′、8′、10′、12′、15′的SpO2、SBP、HR以及异丙酚总用药量、诱导后至被唤醒时间、离院时间、术中意识及不良反应.结果用药后SpO2F组和FK组均有不同程度下降且下降程度无明显区别(p＞0.05),F组SBP、HR也明显下降,而FK组则未见明显变化.FK组异丙酚总用药量明显少于F组(p＜0.01).两组清醒时间、离院时间无显著差别(p＞0.05).结论异丙酚复合小剂量氯胺酮用于无痛人流术可减轻对循环的抑制,减少异丙酚的用量,可安全用于无痛人流术.     

异丙酚复合芬太尼与小剂量氯胺酮在无痛人流术中的临床观察

目的：比较异丙酚复合芬太尼与异丙酚复合小剂量氯胺酮应用于无痛人工流产手术的麻醉效果。方法：90例早孕妇女，随机分为F（芬太尼组）、K（氯胺酮组）、P（异丙酚对照组）三组，观察并记录异丙酚用量、清醒时间、离院时间、麻醉前、麻醉后每两分钟的BP、HR、SPO2及术中、术后不良反应。结果：P组用药量明显高于F组、K组，F组用药量与K组无显著性差异（P〉0．05），P组、F组BP、HR、SPO2均明显下降与K组有显著性差异（P〈0．05）清醒时间及离院时间不良反应率三组无显著性差异（P〉0．05）。结论：芬太尼与氯胺酮均可复合异丙酚有效应用于无痛人流术，但小剂量氯胺酮复合异丙酚更安全可靠。     

小剂量氯胺酮复合异丙酚用于门诊无痛人流术的临床观察

目的 采用小剂量氯胺酮(0.1mg/kg)复合异丙酚进行门诊无痛人流手术,并对比常规芬太尼复合异丙酚方法,分析探讨临床应用价值和可行性.方法 将50例ASA Ⅰ～Ⅱ级无痛人流术患者,随机分为异内酚-氯胺酮组(PK组,n=25)和异内酚-芬太尼组(PF组,n=25),分别观察记录两组循环、呼吸、麻醉效果和清醒时间的变化,对比其差异.结果 异丙酚-氯胺酮组引起循环、呼吸抑制小,麻醉效果较好,但是清醒时间较晚.而异丙酚-芬太尼组引起循环、呼吸抑制较大,但是清醒时间快.结论 小剂量氯胺酮复合异丙酚的方法循环、呼吸影响小,麻醉效果好,是一种可行安全的用于门诊无痛人流术的麻醉方法.     

异丙酚靶控输注在门诊无痛人流手术中的应用

目的：对比异丙酚单次给药与异丙酚靶控输注（TCI）给药两种给药方式对门诊无痛人流手术病人的影响。方法：选择ASAⅠ～Ⅱ级的择期门诊无痛人流病人60例,随机分为异丙酚单次给药组芬太尼1μg／kg＋异丙酚2．5mg／kg（A组）30例,异丙酚TCI组芬太尼1μg／kg＋异丙酚TCI（B组）30例,观察两组的异丙酚总量及苏醒时间,血压和末梢氧饱和度变化趋势。结果：①A组的异丙酚总量及苏醒时间（手术结束至呼之能应时间）均长于B组。②A组血压和末梢氧饱和度下降的趋势较B组明显。结论：异丙酚TCI给药在门诊无痛人流病人用药量少,苏醒快,且对呼吸及循环的影响小。     

异丙酚伍用芬太尼、氯胺酮用于无痛人流的效果比较

目的：探讨异丙酚伍用芬太尼、氯胺酮用于无痛人流手术效果及副作用情况.方法：异丙酚1.5mg/kg＋芬太尼1μg/kg＋氯胺酮0.4mg/kg分别用于人流镇痛各50例,监测镇痛效果,HR、RR、BP、SPO2、出血量、副作用等.结果：两组无痛率相近,用药前后HR、RR、BP、SPO2平稳、出血量相近,均无人流综合症发生.结论：两种复方用药用于无痛人流术均较理想,异丙酚＋芬太尼组较异丙酚＋氯胺酮组更为安全.     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

The clinicopathological and immuohistochemical analysis of solid-pseudopapillary tumor of the pancreas： report of 9 cases

Objective：To investigate the clinical features, pathological characteristics and immunophenotype of solid-pseudopapillary tumor of the pancreas（SPTP）. Methods：Nine surgically treated cases of SPTP were retrospectively reviewed. Hematoxylin and Eosin（HE） staining and immunohistochemical staining were used to analyze all cases, and the general clinical data was collected. Results：Six patients were asymptomatic except for a palpable mass. Two patients complained of vague-epigastric pain. One patient appeared jaundice. The tumor was encapsulated and solid tissues alternately with cystic tissues. Histologically, the histological structure of solid portion was pseudopapillary with a fibrovascular core. Tumor cells were uniform and medium-sized which were arranged in sheets ets or nests or pseudopapillary patterns. Immunohistochemical studies demonstrated that SPTP proved positive in vimentin（9/9 cases）, AAT（9/9 cases）, NSE（9/9 cases）, ACT（7/9 cases）, CK20（2/9 cases）, CgA（1/9 cases）, S-100（3/gcases）, PR（4/gcases）, Syn（3/9 cases） and CD56（5/9cases）, negative in CEA and ER. Conclusion：SPTP is a tumor predominantly occurring in young women frequently without special symptoms. This tumor has various characteristical histological patterns with different immunophenotype.     

Electro-Acupuncture Combined with the Trigger Point Needle-Embedding for Treatment of Primary Trigeminal Neuralgia in 31 Cases

In recent years, the author of this essay has applied electro-acupuncture combined with the trigger point needle-embedding for treatment of primary trigeminal neuralgia in 31 cases, yielding satis- factory results as reported in the following.     

Investigation of Matrix Metalloproteinase -1, 2 and tissue inhibitor of matrix metalloproteinases-1 in Endometriosis

Objective： To explore the role of matrix metalloproteinase-1,2 （MMP-1, MMP-2） and tissue inhibitor of matrix metalloproteinases-1 （TIMP-1） in endometriosis. Methods： The eutopic and ectopic endometria from 40 subjects suffering from endometriosis and regular.endometria from 40 subjects （excluding endometriosis） were collected and examined by in situ hybridization technology and western blot assay. Results： Both expressions of MMP-1 and -2 were stronger in ectopic endometrium and eutopic endometrium than in normal endometrium. On the contrary, the expression of TIMP-1 in ectopic endometrium and eutopic endometrium was lower. The differences were significant （P 〈 0.01 ）. Moreover, there was no relationship among the expressions of MMP-1, 2 and TIMP-1 in ectopic endometrium. Conclusion： The expressions of MMP-1, 2 and TIMP-1 lose balance and lack of periodic changes in ectopic endometrium , which explains the biological invasive behavior of endometriosis. It was suggested-that regulating the balance between the MMPs and TIMP-1 should be an ideal therapeutic target to endometriosis.     

Shi Da-zhuo (史大卓) —An outstanding cardiologist of integrative medicine

Prof. SHI Da-zhuo, Ph.D., male, was born on March 20, 1960. Prof. SHI entered the Ph.D. program in 1990 at the China Academy of Chinese Medical Sciences under the supervision of Prof. CHEN Ke-ji, majoring in the treatment of cardiovascular diseases. After receiving his Ph.D. degree in 1993, Prof. SHI started working at the Cardiovascular Center in Xiyuan Hospital affiliated to China Academy of Chinese Medical sciences.     

Persist in and Carry Forward the Integrative Medical Research——Speech at the 6th National General Congress of Chinese Association of Integrative Medicine by Academician CHEN Zhu,Minister of Ministry of Health

The 6th National General Congress of Chinese Association of Integrative Medicine （CALM） was convened at 19-20, April 2008 in Beijing. Academician CHEN Zhu, the minister of Ministry of Health indicated at the congress that the integration of Chinese and Western medicine is very well in keeping with the situation of our country and the general rule of development in medical science; and as a good integration of Chinese medicine and Western medicine, it is mutually beneficial and advantageous to both of them. Seeing the creativity shown in integrative medical investigation in theoretic and methodological sides, we should and must persist in and develop it.